AFTER THE 14th_ELSF
> RECORDINGS​
> ATTENDEES​
> INVESTORS​
> PRESENTERS​
> SPONSORS​
> SUPPORTERS​

Sachs Associates would like to say we enjoyed hosting a virtual conference and thank those who participated in our Sachs Spring Life Sciences Week, which incorporated the 2nd Annual European HealthTech CEO Forum (EHTF) and the 14th Annual European Life Sciences CEO Forum (ELSF). A special thank you goes to the excellent line up of sponsors, chairpersons, panelists and presenters who made such a broad and interesting programme possible.
​
The virtual conference is proving successful in supporting our community with 525 people from 29 countries registered, over 10,000 messages sent, and nearly 1300 meetings completed during the Sachs Spring Life Sciences Week.
​
We look forward to seeing you in our future events !

SPOTLIGHT PRESENTERS:

PRESENTING COMPANIES:

CONFIRMED KEYNOTE SPEAKERS INCLUDED:

• Keynote: “EIT Health Accelerator: How we facilitate expertise and investment opportunities in the European healthcare sector” by Kurt Höller, Director of Business Creation, EIT Health e.V.
• Big Pharma Fireside Chat with Nigel Sheail, Global Head of M&A and BD&L, Novartis International AG, moderated by Je­ffrey Bockman, EVP, Head of Oncology Practice, Cello Health BioConsulting.
• Introductory Speech by Sandra Ferri, Head of Life Sciences, European Investment Fund
• Keynote: “How China is Transforming the Clinical Development Landscape & the Biopharma Industry”​ By John Oyler, Co-Founder, Chairman & CEO, BeiGene Ltd.

SPEAKERS & CHAIRS INCLUDED:

• Adam Kostyál, SVP of the Global Listing Services & Head of European Listings, Nasdaq
• Andreas Hohn, Director of Transaction Excellence, Roche Partnering, F. Hoffmann-La Roche Ltd.
• Anker Lundemose, CEO, Mission Therapeutics Ltd
• Aram Mangasarian, CEO, NOXXON Pharma NV
• Ashish Patel, Principal, Optum Ventures
• Bibhash  Mukhopadhyay, Principal, New Enterprise Associates (NEA)
• Carlos de Sousa, CEO, Ultimovacs ASA
• Carlos Buesa, Founder & CEO, Oryzon Genomics S.A.
• Chris Maggos, Managing Director, Head of Europe, LifeSci Advisors
• Christophe Bourrilly, Head of Healthcare, Oddo BHF  co-chair for European Capital Markets Panel
• Corinne Venot, Senior Director, Business Development, BeiGene Ltd.
• Dennis Purcell, Founder, Aisling Capital LLC
• Duncan Young, Director, Search & Evaluation, Oncology R&D, AstraZeneca
• Ed Zhang, Venture Partner, Hillhouse Capital
• Eric Halioua, President & CEO, PDC*line Pharma SA
• Erik Manting, CBO, Immunicum AB
• Esteban Pombo-Villar, CEO, TargImmune Therapeutics AG
• Fabian Buller, CBO, Neurimmune AG
• Fintan Walton, Founder & CEO, PharmaVentures Ltd.
• Gil Bar-Nahum, Managing Director, EMEA Head of Biotechnology, Jefferies International Ltd.
• Guillaume Vignon, SVP, Business Development, BeiGene Ltd.
• Hans Schambye, CEO, Galecto, Inc.
• Heinz Lubenau, Co-Founder & CEO, VAXIMM
• Helen Chen, Greater China Managing Partner & Head of China Life Sciences, L.E.K. Consulting
• Hubert Birner, Managing Partner, TVM Life Science Management GmbH
• Ioannis Sapountzis, Corp. SVP, Global Head of BD&L, Boehringer Ingelheim International GmbH
• Jay Olson, Managing Director & Senior Analyst, Oppenheimer & Co. Inc.
• Jeffrey Bockman, EVP, Head of Oncology Practice, Cello Health BioConsulting
• Jennifer Laird, Vice President, Search & Evaluation – Neuroscience, Eli Lilly and Company
• Jesús Martin-Garcia, CEO, GeNeuro S
• Jo Pisani, Strategic Advisor, Non Executive Director & Charity Trustee, UK Dementia Research Institute
• John Baker, SVP, Product Portfolio & Innovation, Abcam PLC
• John Chin, Chief Business Officer, Antengene Biotech
• Jonathan Wang, SVP, Head of Business Development, Zai Lab Ltd.
• Katya  Smirnyagina, Executive Director, Capricorn Partners NV
• Khatereh Ahmadi, Executive Director, Oncology Search & Evaluation Lead for Europe, MSD
• Lior Teitelbaum, CBO, FutuRx Ltd.
• Lynn Durham, Founder, CEO, STALICLA S.A.
• Matthew Stork, CEO, Cambridge Cognition Ltd.
• Matthias Müllenbeck, SVP, Head Global BD & Alliance Management, Merck KGaA
• Melissa McCracken, Principal, Nextech Invest Ltd.
• Michael Altorfer, CEO, Swiss Biotech Association
• Michael Margolis, Managing Director, Co-Head Healthcare & Head of Life Sciences, Oppenheimer & Co. Inc.
• Michael Mulqueen, VP Business Development, eTheRNA immunotherapies NV
• Michael Rice, Founding Partner, LifeSci Advisors
• Michael Rice, Principal, Head of Advanced Therapeutics, Cello Health BioConsulting
• Mike Romanos, Co-Founder & CEO, Microbiotica Ltd.
• Nathalie ter Wengel, European Lead, Worldwide Business Development, Pfizer, Inc.
• Naveed Siddiqi, Senior Partner, Novo Holdings A/S
• Nigel Sheail, Global Head of M&A and BD&L, Novartis International AG
• Olav Zilian, Senior Healthcare Analyst, VP, Mirabaud Securities Ltd.
• Otello Stampacchia, Managing Director, Omega Fund Management (US), Inc.
• Patrick Benz, Sr. Director Alliance Management, The Janssen Pharmaceutical Companies of Johnson & Johnson
• Paul Hermant, Partner, Bird & Bird LLP
• Philippe Verwaerde, CEO, AlzProtect
• Pierre-Jean Wip­, Innovation Advisor, Innovaud
• Priyanka Belawat, Investment Advisor Private Equity, HBM Partners AG
• Rainer Strohmenger, Managing Partner, Wellington Partners
• Reagan Jarvis, Co-Founder & CEO, Anocca AB
• Richard Godfrey, CEO, BerGenBio ASA
• Sascha Bucher, Founder, Forty51 Ventures
• Sam Fazeli, Head of Research, Senior Pharmaceuticals Analyst, Bloomberg Intelligence
• Sander van Deventer, Operating Partner, Forbion
• Sandra Ferri, Head of Life Sciences, European Investment Fund*
• Sébastien Petitet, Chief Business Development Officer, Brenus Pharma
• Sofia Ioannidou, Partner, Andera Partners
• Søren Møller, Managing Partner, Novo Seeds, Novo Holdings A/S
• Stephanie Léouzon, Partner & Head of Europe, Torreya Partners LLP
• Sumant  Kulkarni, Managing Director, Biotechnology Equity Research, Canaccord Genuity LLC
• Ted Fjällman, CEO, Prokarium Ltd.
• Thibaut Roulon, Senior Investment Director, Bpifrance
• Tim Haines, Chairman & Managing Partner, Abingworth
• Tomas Landh, Innovation Sourcing VP, Senior Principal Scientist R&D Global Search & Evaluation, Novo Nordisk A/S
• Wesley Holmes, Partner, Latham & Watkins LLP
• Yochi Slonim, Co-Founder & CEO, Anima Biotech, Inc.
• Zhihong Chen, President & CEO, Curon Biopharmaceutical

SILVER SPONSORS:

BRONZE SPONSOR:

---

CONTRIBUTING SPONSORS:

---

​SUPPORTERS:

---

PARTICIPATING PHARMAS:

---

​FINANCIAL, ADVISORY, INVESTORS ATTENDING:

3B Future Health Fund (formerly Helsinn Investment Fund)
3B Future Health Ventures Sarl (Helsinn Investment Fund)
3E Bioventures
4BIO Capital
AbbVie Deutschland GmbH Co. KG
AbbVie Ventures
Abingworth LLP
ACXIT Capital Management GmbH
Additio Investment Group
Advent Life Sciences
aescuvest international GmbH
Aglaia Oncology Funds
Aisling Capital LLC
ALSA Ventures
Altitude Investment Management
Andera Partners
Aqua Partners LLC
ARCH Venture Partners
Arix Bioscience Plc.
ARTO AG
Asabys Partners
​
To View All - Click Here